May 18, 2015
Mitsubishi Tanabe Pharma Corporation (MTPC) filed on May 15 for an additional indication of Kawasaki disease for its anti-human TNFα monoclonal antibody Remicade for IV Infusion 100 (infliximab), it said on the same day. The company conducted a clinical study...read more